Prion Protein as a Receptor for Amyloid-Beta Oligomers
US-2016176972-A1 · Jun 23, 2016 · US
Anti-PrP antibodies and uses thereof
US10808034B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10808034-B2 |
| Application number | US-201716093687-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 4, 2017 |
| Priority date | Apr 15, 2016 |
| Publication date | Oct 20, 2020 |
| Grant date | Oct 20, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides antibodies and antigen-binding fragments capable of binding PrP C . The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
First claim
Opening claim text (preview).
We claim: 1. An antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment comprises a VH CDR1 having the amino acid sequence of SEQ ID NO: 5, a VH CDR2 having the amino acid sequence of SEQ ID NO: 6, and a VH CDR3 having the amino acid sequence of SEQ ID NO: 7, and comprises a VL CDR1 having the amino acid sequence of SEQ ID NO: 14, a VL CDR2 having the amino acid sequence of SEQ ID NO: 15, and a VL CDR3 having the amino acid sequence of SEQ ID NO: 16. 2. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a light chain variable (VL) domain and a heavy chain variable (VH) domain; wherein the VL domain comprises CDR1, CDR2 and CDR3 of the amino acid sequence set forth in SEQ ID NO: 13. 3. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises a light chain variable (VL) domain and a heavy chain variable (VH) domain; wherein the VH domain comprises CDR1, CDR2 and CDR3 of the amino acid sequence set forth in SEQ ID NO: 4. 4. The antibody or antigen-binding fragment of claim 1 , wherein the VH domain comprises framework regions that are at least 90% identical to the amino acid sequences of one or more of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11. 5. The antibody or antigen-binding fragment of claim 1 , wherein the VL domain comprises framework regions that are at least 90% identical to the amino acid sequences of one or more of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20. 6. The antibody or antigen-binding fragment of claim 1 , wherein the VH domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 4 and/or the VL domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 13. 7. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment is humanized or human. 8. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment is encoded by a nucleic acid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 3 or a nucleotide sequence that is at least 90% identical to SEQ ID NO: 12. 9. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment competes with 6D11 antibody for binding to PrP c . 10. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment binds to one or more of human, rat, mouse, or cynomolgus monkey PrP c . 11. A composition comprising a pharmaceutically acceptable carrier and the antibody or antigen-binding fragment of claim 1 . 12. A kit comprising the antibody or antigen-binding fragment of claim 1 .
Assignees
Inventors
Classifications
from primates, e.g. man · CPC title
- C07K16/2872Primary
against prion molecules, e.g. CD230 · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Single chain antibody (scFv) · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10808034B2 cover?
- The present disclosure provides antibodies and antigen-binding fragments capable of binding PrP C . The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
- Who is the assignee on this patent?
- Medimmune Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2872. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).